This Article Full Text Full Text (PDF) All Versions of this Article: 37/9/2288    most recent 01.STR.0000236636.39235.4fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by González-Conejero, R. Search for Related Content PubMed PubMed Citation Articles by González-Conejero, R. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Stroke Related Collections Coagulation Acute Cerebral Infarction Emergency treatment of Stroke Thrombolysis

(Stroke. 2006;37:2288.)
© 2006 American Heart Association, Inc.

Original Contributions

Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients

Rocio González-Conejero, PhD; Israel Fernández-Cadenas; Juan A. Iniesta, MD, PhD; Joan Marti-Fabregas, MD, PhD; Victor Obach, MD; José Alvarez-Sabín, MD, PhD; Vicente Vicente, MD, PhD; Javier Corral, PhD; Joan Montaner, MD, PhD for the Proyecto Ictus Research Group

From the Centro Regional de Hemodonación (R.G.-C., V.V., J.C.), Universidad de Murcia, Murcia, Spain; the Neurovascular Research Laboratory (I.F.-C., J.A.S., J.M.), Stroke Unit, Departamento de Medicina, Universidad Autónoma de Barcelona, Hospital Vall d’Hebron, Barcelona, Spain; the Neurology Section (J.A.I.), Hospital General Universitario, Murcia, Spain; the Stroke Unit (J.M.-F.), Hospital Sant Pau, Barcelona, Spain; and the Stroke Unit (V.O.), Hospital Clinic, Barcelona. Spain.

Correspondence to Dr Javier Corral, Centro Regional de Hemodonación., C/Ronda de Garay s/n, Murcia 30003, Spain. E-mail javier.corral{at}carm.es

Background and Purpose— The identification of genetic and environmental factors that could improve the benefit/risk ratio of thrombolytic therapy in patients with ischemic stroke is crucial.

Methods— We studied the role in the efficacy and side-adverse effects of thrombolytic therapy in stroke of 2 factors involved in the structure and stability of fibrin clot: fibrinogen levels and factor XIII (FXIII) V34L, a common and functional polymorphism. Our study enrolled 200 consecutive patients with stroke who received intravenous recombinant tissue plasminogen activator.

Results— Patients with FXIII V/V genotype and low fibrinogen (<3.6 g/L) displayed the best clinical outcome. In contrast, carriers of the L34 variant and high fibrinogen levels showed almost no clinical response. Moreover, patients with high fibrinogen levels at admission displayed higher mortality than patients with lower fibrinogen levels (22.6% versus 9.7%, P=0.027; OR=2.72). The FXIII V34L polymorphism also associated with mortality: 20.0% of L34 carriers but 9.1% of patients with V/V genotype died after thrombolytic therapy (P=0.034; OR=2.50). The deleterious effect of this variant seemed to be exacerbated by high levels of fibrinogen, supporting the role of fibrinogen levels in determining the hemostatic consequences of the FXIII polymorphism.

Conclusions— Our study identifies 2 markers involved in fibrin formation associated with the efficacy of thrombolytic therapy and early mortality rates in patients with ischemic stroke. These markers could be useful to identify patients with stroke suitable for a safe thrombolytic therapy.

Key Words: genetics • risk factors • stroke • thrombolysis

This article has been cited by other articles:

				F. Marin, R. Gonzalez-Conejero, P. Capranzano, T. A. Bass, V. Roldan, and D. J. Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1041 - 1057. [Abstract] [Full Text] [PDF]

				G. J. del Zoppo, D. E. Levy, W. W. Wasiewski, A. M. Pancioli, A. M. Demchuk, J. Trammel, B. M. Demaerschalk, M. Kaste, G. W. Albers, and E. B. Ringelstein Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke Stroke, May 1, 2009; 40(5): 1687 - 1691. [Abstract] [Full Text] [PDF]